Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

13.22
+0.71005.68%
Post-market: 13.220.00000.00%19:30 EDT
Volume:851.70K
Turnover:11.13M
Market Cap:609.77M
PE:16.73
High:13.43
Open:12.53
Low:12.29
Close:12.51
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:1.01
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7900
EPS(LYR):1.80
ROE:16.40%
ROA:3.99%
PB:2.04
PE(LYR):7.34

Loading ...

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewswire
·
May 07

Oddity Tech (ODD) Is Down 8.5% After Class Action Over Ad Cost Disclosures - What's Changed

Simply Wall St.
·
May 02

A Look At Oddity Tech (ODD) Valuation After Class Action Lawsuit On Advertising Disclosures

Simply Wall St.
·
May 01

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire
·
Apr 30

Oddity price target lowered to $14 from $18 at Jefferies

TIPRANKS
·
Apr 29

Creating a Sustainable Impact: Fosun International Releases 2025 ESG Report and Climate Information Disclosures Report

prnewswire
·
Apr 28

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

GlobeNewswire
·
Apr 27

Oddity Tech faces shareholder class action over alleged advertising cost disclosure omissions

Reuters
·
Apr 23

Radiopharm Theranostics Reports Business Update

GlobeNewswire
·
Apr 23

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies

GlobeNewswire
·
Apr 21

Medicus Pharma submits ODD application to U.S. FDA for SkinJect

TIPRANKS
·
Apr 17

ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep

The West Australian
·
Apr 17

Oddity Tech faces securities class action over alleged misleading ad efficiency disclosures

Reuters
·
Apr 16

A Look At Oddity Tech (ODD) Valuation As Securities Class Action Raises Questions On Customer Acquisition Costs

Simply Wall St.
·
Apr 11

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire
·
Apr 09

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results

GlobeNewswire
·
Apr 09

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

GlobeNewswire
·
Apr 08

Kodiak AI Expands Autonomous Trucking Beyond the Sunbelt with Demonstrations in Ohio and Indiana

GlobeNewswire
·
Apr 08

Oddity Tech (ODD) Faces Investor Lawsuit Over Alleged Ad Algorithm Disclosures

TIPRANKS
·
Apr 08

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

GlobeNewswire
·
Mar 30